76 results
POS AM
QNRX
Quoin Pharmaceuticals Ltd
29 Mar 24
Prospectus update (post-effective amendment)
4:11pm
assessment of two different doses of QRX003 versus a placebo vehicle in 18 adult NS patients. The test materials are applied once daily, over a twelve-week … in the study, including but not limited to, an Investigators Global Assessment (IGA), Patient’s Global Assessment (PaGA) and Pruritis.
In November 2022
424B4
QNRX
Quoin Pharmaceuticals Ltd
6 Mar 24
Prospectus supplement with pricing info
5:07pm
, double blinded assessment of two different doses of QRX003 versus a placebo vehicle in NS patients. The test materials are applied once daily, over … are being assessed in the study, including but not limited to, an Investigators Global Assessment (IGA), Patient’s Global Assessment (PaGA) and Pruritis
424B3
QNRX
Quoin Pharmaceuticals Ltd
4 Mar 24
Prospectus supplement
5:27pm
are actively being screened and recruited into the study and dosing commenced in December 2022. This study is a randomized, double blinded assessment … , including but not limited to, an Investigators Global Assessment (IGA), Patient’s Global Assessment (PaGA) and Pruritis.
In November 2022, we submitted
424B3
rfgdx1rajux o3
9 Nov 23
Prospectus supplement
5:15pm
8-K
EX-99.1
t1t4dlahfutu 4a1f
9 Nov 23
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
5:10pm
424B3
0elbn ziazssnzu4afe
14 Sep 23
Prospectus supplement
4:38pm
8-K
EX-10.1
8xroe9px8g9i1d nz6
12 Sep 23
Entry into a Material Definitive Agreement
6:01pm
DEF 14A
iu7n0aniuktlf
12 Sep 23
Definitive proxy
6:03am
PRE 14A
0etz g6po
1 Sep 23
Preliminary proxy
1:38pm
424B3
5l0zryzy
3 Aug 23
Prospectus supplement
4:51pm
424B3
82nys
9 May 23
Prospectus supplement
4:03pm
10-Q
yv3j4h5aw8p9sm9x
9 May 23
Quarterly report
3:03pm
424B3
u42dega8 w9
10 Nov 22
Prospectus supplement
12:45pm
424B3
jmx u1m1jv1w
10 Nov 22
Prospectus supplement
12:43pm
6-K
EX-99.2
1qma6h34
10 Nov 22
Current report (foreign)
11:08am